Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $67.78

Posted by Brian Himes on Jul 29th, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received an average rating of “Moderate Buy” from the nineteen analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $67.7778.

Several research firms recently weighed in on CRSP. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Evercore reiterated an “outperform” rating and set a $76.00 target price on shares of CRISPR Therapeutics in a research note on Monday, May 11th. UBS Group set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 12th. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, July 22nd. Finally, Citizens Jmp reissued a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th.

Check Out Our Latest Stock Report on CRISPR Therapeutics

Insider Activity

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in CRSP. GSK plc bought a new position in CRISPR Therapeutics in the 4th quarter worth about $168,890,000. Orbis Allan Gray Ltd increased its position in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after buying an additional 1,201,600 shares during the period. State Street Corp lifted its holdings in shares of CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock valued at $551,777,000 after acquiring an additional 735,084 shares during the period. Finally, Norges Bank bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $25,706,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Up 1.8%

NASDAQ CRSP opened at $47.55 on Friday. The firm has a market capitalization of $4.59 billion, a P/E ratio of -7.64 and a beta of 1.71. The business has a fifty day simple moving average of $52.62 and a 200 day simple moving average of $52.55. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million for the quarter. On average, analysts predict that CRISPR Therapeutics will post -4.9 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.